Revolutionising EBV Prevention with a First-in-Class Oral Vaccine
Thermostable, self-administered vaccines developed with cutting-edge AI-driven antigen design
iosBio is developing transformative oral vaccines using proprietary platforms to tackle major infectious diseases. Our lead candidate, OraPro-EBV, targets Epstein-Barr Virus – a significant unmet need linked to Multiple Sclerosis, mononucleosis, and several cancers. Discover how our thermostable OraPro™ technology, Enhanced Surface Display (ESD), and AI-driven antigen design are creating the future of vaccination.
Addressing Critical Unmet Needs in Vaccination
Over 90% of adults are infected with Epstein-Barr Virus, driving diseases like multiple sclerosis and cancer with no approved vaccine available. Traditional vaccines face challenges with cold chain logistics, needle administration, and mucosal immunity. iosBio tackles these problems head-on
Advancing our Lead Oral EBV Vaccine
OraPro-EBV has shown outstanding preclinical results, inducing class-leading antibody responses against key viral targets. We are preparing for a Phase 1 clinical trial.
Proprietary Platforms Driving Innovation
OraPro™ platform
The OraPro™ vaccine platform delivers needle-free, thermostable vaccines orally, eliminating cold-chain dependencies, enhancing global accessibility and generates mucosal & systemic immunity through self-administered capsules.
Enhance Surface Display (ESD™) platform
iosBio’s patented ESD™ technology significantly enhances antigen visibility to the immune system, driving stronger, faster, and longer-lasting immune responses compared to conventional methods.
AI-Assisted Antigen Design
Leveraging advanced artificial intelligence, iosBio accelerates vaccine development by optimizing antigen design for maximum immunogenicity and protection, drastically reducing time from discovery to delivery.
Partner with Us to Transform Vaccination
We are currently raising £12-30m to advance OraPro-EBV into the clinic. Join us in addressing a significant market opportunity and changing the future of global health.